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To through light on the mechanisms underlying the stimulation and persistence of glial cell activation in Parkinsonism, we
investigate the function of IFN-c and TNF-a in experimental models of Parkinson’s disease and analyze their relation with local
glial cell activation. It was found that IFN-c and TNF-a remained higher over the years in the serum and CNS of chronic
Parkinsonian macaques than in untreated animals, accompanied by sustained glial activation (microglia and astroglia) in the
substantianigraparscompacta.Importantly,ParkinsonianmonkeysshowedpersistentandincreasinglevelsofIFN-cRsignaling
in both microglial and astroglial cells. In addition, experiments performed in IFN-c and TNF-a KO mice treated with MPTP
revealedthat,evenbeforedopaminergiccelldeathcanbeobserved,thepresence ofIFN-candTNF-aiscrucialformicroglialand
astroglial activation, and, together, they have an important synergistic role. Both cytokines were necessary for the full level of
activation to be attained in both microglial and astroglial cells. These results demonstrate that IFN-c signaling, together with the
contribution of TNF-a, have a critical and cell-speciﬁc role in stimulating and maintaining glial cell activation in Parkinsonism.
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Parkinson’s disease (PD) is characterized by the rapid and
unpredictable loss of dopaminergic neurons located in a small
mesencephalic nucleus, the Substantia Nigra pars compacta
(SNpc), the cause of which remains unknown. Recent
evidence has demonstrated that local inﬂammation, primarily
mediated by glial cells, may contribute to this neuronal
degeneration. In fact, post-mortem analysis of the SNpc of
PD patients has revealed increased numbers of activated
microglial
1 and astroglial cells,
2 reﬂecting persistent inﬂam-
mation and consequent active nerve degeneration. Likewise,
the post-mortem study of a group of drug addicts accidentally
intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a neurotoxin that speciﬁcally kills dopaminergic
neurons, showed the same maintained glial reaction in the
SNpc many years after the neurotoxin insult.
3 Importantly,
experimentally induced Parkinsonian monkeys showed an
identical glial response years after MPTP injection, which was
also conﬁned to the SNpc.
4,5 This indicates that the glial
reaction and inﬂammatory response persist over many years
in Parkinsonian subjects (human and non-human primates)
despite the absence of any apparent new neurotoxic insult
that might induce this state. However, the mechanisms
involved in the perpetuation of this glial activation in the SNpc
remain unclear.
Pro-inﬂammatory cytokines are clear candidates to be
implicated in the initiation and self perpetuation of glial
activation in the brain.
6,7 Some of these pro-inﬂammatory
cytokines
8–10 show increased levels in the blood serum of
patients with PD and post-mortem analysis of PD patients’
brains show a concomitant increase of these cytokines in the
nigrostriatal system.
10 However, the function of this cytokine-
mediated inﬂammatory reaction observed in the brain, and
also outside the central nervous system (CNS), is poorly
understood, as is the way in which normal resting glia become
activated. It is known that some cytokines, like interferon-g
(IFN-g) and tumor necrosis factor-a (TNF-a), may be involved
in dopaminergic degeneration, and the absence of either
protects dopaminergic neurons in experimental models of PD
in mice.
8,11,12 In the present work, we show how IFN-g and
TNF-a are critically involved in the triggering and perpetuation
of glial activation in vivo, in two animal models of PD. In the
ﬁrst model of chronic Parkinsonian monkeys, we investigate
the putative role of IFN-g and TNF-a in a sustained glial
inﬂammatory response in the SNpc. We demonstrate that
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www.nature.com/cddisIFN-g signaling, with the contribution of TNF-a, may have a
crucial role in stimulating the persistent activation of both
microglia and astrocytes in a cell-speciﬁc manner. The
amount of glial IFN-g increased in the SNpc of Parkinsonian
monkeys and was strongly correlated with dopaminergic
neuronal degeneration. Importantly, STAT1, a crucial tran-
scription factor activated in response to IFN-g, remains
phosphorylated locally in glial cells of the SNpc of Parkinso-
nian monkeys years after MPTP exposure. However, while
TNF-a also remained high in MPTP-treated monkeys, it did
not correlate so strongly with the dopaminergic loss. In the
second model, using KO mice lacking IFN-g or TNF-a,w e
investigated the particular role of IFN-g and TNF-a in glial
activation before dopaminergic neuronal loss could occur
andobservethatbothcytokinesareresponsibleforenhancing
the activation of the surrounding glial cells in a reciprocal
manner. These results throw light on which cytokines are
speciﬁcally involved in the glial-mediated inﬂammatory
response in Parkinsonism and suggest two speciﬁc
therapeutic targets (IFN-g and TNF-a) to diminish local
inﬂammation in PD.
Results
Increase of IFN-c and TNF-a in blood serum of
Parkinsonian monkeys. Serum samples from 20 young
MPTP-treated adult macaques were analyzed to elucidate
which pro-inﬂammatory cytokines may be involved in chronic
Parkinsonism. Susceptible MPTP-treated monkeys
(Parkinsonian) showed Parkinsonian symptoms, displaying
sporadic freezing phenomena and different degrees of
bradykinesia and akinesia, while some presented action
tremor, paradoxical kinesia and, occasionally, vertical and
horizontal saccadic ocular movements. However, some
monkeys did not show Parkinsonian symptoms
(asymtomatic) despite the numerous MPTP injections
(Table 1). Susceptible monkeys also displayed a typical
Parkinsonian posture (Figures 1a and b) in contrast to the
asymptomatic animals that showed postures similar to
controls. Before the postmortem analysis were conducted,
several characteristic pro-inﬂammatory cytokines, IFN-g,
TNF-a, IL-16, IL-6, IL-8 and TNF-b, were measured in
blood serum samples of the MPTP-treated monkeys.
Importantly, we observed a sustained increase of IFN-g
and TNF-a, (Figures 1c and d) in contrast with other pro-
inﬂammatory cytokines (Supplementary Figure 1) as
demonstrated by ELISA measurements. Note that IL-1b
was not included in this study because no changes were
observed in this cytokine in a previous analysis performed in
chronic Parkinsonian monkeys.
13
Before proceeding with a deeper analysis of these two
cytokines in the CNS, we analyzed the level of dopaminergic
degeneration and gial activation in the MPTP-treated mon-
keys. When dopaminergic neuronal loss was analyzed in the
SNpc of MPTP-treated monkeys, only monkeys with evident
Parkinsonian symptoms presented a high degree of dopami-
nergic neuronal loss (Supplementary Figure 2a). However,
asymptomaticmonkeysshowedacertain,non-signiﬁcantloss
with respect to control animals (Supplementary Figure 2a).
Parkinsonian animals showed increased levels of both
microglial and astroglial activation, as demonstrated, by the
expression of HLA-DR and GFAP markers, respectively, and
Table1 Valuesofthemotorscorereachedbythemonkeys,accumulativedose
of MPTP (mg/kg) of each animal and the time of killing after the last MPTP dose
Monkey Sex Motor Score
MPTP
Accumulative
dose mg/kg
Years after
last MPTP
dose
C1 Male 0.0 0 —
C2 Male 0.0 0 —
C3 Female 0.0 0 —
C4 Male 0.0 0 —
C5 Male 0.0 0 —
C6 Male 0.0 0 —
A1 Male 0.0 1.8 1
A2 Male 0.0 1.8 1
A3 Male 0.0 2.1 1
A4 Male 0.0 1.8 1
A5 Male 0.0 1.8 1
A6 Female 0.0 0.9 1
P1 Male 3.5 1.8 1
P2 Female 4.2 0.9 2
P3 Male 5.0 1.8 1
P4 Female 9.2 0.9 2
P5 Male 10.0 3.9 1
P6 Male 10.0 4.2 5
P7 Male 15.0 3.6 5
P8 Male 17.0 2.1 1
Abbreviations: A, asymptomatic animals; C, control animals; P, Parkinsonian animals
Figure 1 Persistent increase of IFN-g and TNF-a in chronic Parkinsonian
monkeys. (a–d) Artist’s sketch (a) of the typical gait posture of a normal monkey
(control) compared with the characteristic Parkinsonian posture (Parkinsonian).
Parkinsonian monkey posture is characterized by curvature of the trunk and rigidity
of the limbs, together with rigidity of the tail (drawings by C.B). (b) Graphs of the
motor score impairment reached by the MPTP-treated monkeys included in the
study. Some animals, despite MPTP administration, did not show symptoms
(asymptomatic). (c) Levels of IFN-g measured by ELISA in serum increase in
Parkinsonian monkeys. (d) Levels of TNF-a measured by ELISA in serum are
increased in Parkinsonian monkeys. *Po0.05 respect to non-Parkinsonian
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Cell Death and Diseaseby phenotypical changes in both cell types (Supplementary
Figures2b,2cand3).Thegroupofanimalskilled5yearsafter
the last MPTP dose showed slightly higher glial activation,
althoughthe numberofanimalsinthis group(5years)wastoo
small (n¼2) for any statistical differences to be established.
Moreover, the animals from this group had higher motor
scores and suffered greater dopaminergic neuronal loss,
which may bias any observations. Previous studies have
shown that glial activation maintains similar levels despite
acute or chronic protocols of MPTP administration.
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Taken together, these results conﬁrm that in our model of
Parkinsonian macaques, glial cells remain activated over a
number of years. However, since it was thought that pro-
inﬂammatory cytokines may be involved in glial cell activation,
weproceededtoanalyzeIFN-gandTNF-alevelsintheCNSof
the Parkinsonian monkeys.
Increase of IFN-c in the CNS of Parkinsonian monkeys.
Sections of the SNpc were stained with antibodies against
IFN-g and western blot analysis was performed in
homogenates of the SNpc to test the speciﬁcity of the
antibodies and to quantify the amount of IFN-g. Few IFN-g
þ
cells were seen in the control animals, whereas, MPTP-
treated animals showed a dramatic increase in IFN-g
þ cells
in the SNpc (Figures 2a and b). Furthermore, this increase
was more pronounced in animals with evident clinical
symptoms. Western blot analysis demonstrated the
speciﬁcity of the IFN-g antibody, and pointed to a similar
increase of IFN-g in the SNpc of Parkinsonian monkeys
(Figure 2c). Importantly, the amount of IFN-g was
closely correlated with motor impairment and dopaminergic
cell death (Table 2). There was also a correlation with
microglial activation, especially as regards phenotypical
changes, but a weak correlation with astroglial activation
(Table 2).
ToidentifytheIFN-g-expressingcelltype,adjacentsections
were stained with an antibody against IFN-g combined with
antibodies against Iba-1 or GFAP. Surprisingly, IFN-g
immunoreactivity was primarily observed in the microglia
(Iba-1
þ cells), but was absent in the astroglia (GFAP
þ cells)
(Figure 2d), which suggests that microglial cells may produce/
release or accumulate IFN-g in the SNpc of Parkinsonian
monkeys. Interestingly, when the IFN-g-expressing microglial
cells were analyzed by detailed confocal microscopy, some
microglial cells showed peri-nuclear IFN-g staining (Figure
2e1), while other cells, with an activated morphology
(increased cell body size and a higher number of ramiﬁca-
tions), expressed IFN-g throughout the entire cytoplasm (cell
bodyand ramiﬁcations)(Figure 2e2). Inaddition, this increase
in IFN-g-expressing cells corresponded to a higher percen-
tage of microglial cells that express IFN-g in chronic
Parkinsonism (Figure 2f).
Evidence of IFN-cR signaling by glial cells in the SNpc of
chronic Parkinsonian monkeys. Given the increased
expression of IFN-g in the SNpc of chronic Parkinsonian
monkeys, the expression of IFN-g receptor (IFN-gR) was
studied in monkey brain sections to ascertain which cell
types were affected by IFN-g signaling. It was observed that
both microglial cells and astroglial cells are able to express
IFN-gR, as demonstrated by multiple immuno-ﬂuorescence
(Figure 3). Most importantly, as the phosphorylation of
STAT1 is essential for responsiveness to IFN-g, through
stimulation of the IFN-gR, we analyzed the expression of
phosphorylated STAT1 (pSTAT1) in the SNpc of chronic
Parkinsonian monkeys, ﬁnding that the number of pSTAT1-
expressing cells was greatly increased in Parkinsonian
animals compared with the control (Figures 4a and b).
Furthermore, we also observed that the increase of pSTAT1
expression was speciﬁc for the SNpc and was not observed
in other uninvolved brain regions (Supplementary Figure 4).
In addition, the expression of pSTAT1 was seen in both
microglial and astroglial cells (Figures 4c and d), which
demonstrates that IFN-g signaling may be involved in the
sustained glial activation of both cell types in the SNpc.
TNF-a increases in the CNS of Parkinsonian monkeys.
As stated above, we observed a sustained increase of TNF-a
in chronic Parkinsonian monkeys, as demonstrated by ELISA
measurements in serum. Immunohistochemistry in brain
sections using an antibody against TNF-a revealed a
pronounced increase of TNF-a
þ cells in the SNpc of
Parkinsonian monkeys. (Figures 5a and b). Western blot
analysis of homogenates of the SNpc corroborated the
speciﬁcity of the antibody and revealed that MPTP-treated
animals presented high levels of TNF-a, the degree of which
was correlated with their Parkinsonian symptoms and with
the level of neuronal degeneration (Figure 5c and Table 2).
However, poor correlation was seen between glial activation
and the amount of TNF-a measured by western blot (Table 2)
probably because of the similar levels shown by
asymptomatic and Parkinsonian monkeys. To identify the
cell type-expressing TNF-a, adjacent sections of the SNpc
were also stained with the antibody against TNF-a combined
with antibodies against Iba-1 or GFAP. Confocal images
demonstrated that TNF-a
þ immunoreactivity was primarily
observed in astrocytes, but was very faint or absent in
microglia (Figures 5d and e). Moreover, this increase in
TNF-a-expressing cells corresponded to a higher
percentage of astrocytes that express TNF-a several
years after MPTP insult than observed in intact animals
(Figure 4f).
IFN-c is crucial for microglial activation and TNF-a exerts
a synergistic effect. On the basis of the observations
described above and the fact that IFN-g is highly expressed
in microglia and TNF-a is highly expressed in astroglia in the
SNpc of chronic Parkinsonian monkeys, we used a model of
glial activation in KO mice lacking IFN-g or TNF-a to ascertain
whether the absence of one of these cytokines may have a
differential impact on glial activation. Taking advantage of the
fact that MPTP exerts a rapid glial activation in mice within
24h (Supplementary Figure 5), KO mice were injected with a
single dose of MPTP (20mg/kg) and killed before
dopaminergic neuronal loss could be observed (24h after
MPTP). IFN-g( / ), TNF-a( / ) and wild-type mice of the
same age and background (C57BL6) were injected with
MPTP and killed 24h later. Microglial and astroglial activation
were analyzed with confocal microscopy, bearing in mind the
criteria described in the Material and Methods section
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Cell Death and Disease(Supplementary Figure 6). Before dopaminergic loss could
be observed (Figure 6a), wild-type mice (C57BL-6) showed a
speciﬁc activation of microglial cells in the SNpc,
characterized by an increase in F4/80 expression
(Figure 6b), a pronounced increase in cell body size
(Figures 6c and d) and also by an increased number of
primary and secondary branches and terminal tips
(Figure 6e).
Importantly, in mice lacking IFN-g (IFN-g( / )), microglial
activation was severely affected. First of all, no changes in the
Figure 2 Increase of IFN-g in the SNpc of Parkinsonian monkeys. (a–f): Increase of IFN-g
þ cells in brain sections of the SNpc of Parkinsonian monkeys. (a) Confocal
images of immunoﬂuorescence against IFN-g revealed a higher number of IFN-g
þ cells in MPTP-treated animals. Scale bar: 100mm. (b) The density of cells was estimated
bystereologicalcriteria andasigniﬁcantincreaseinIFN-g
þ cellswasobservedinMPTP-treated animals.(c)Westernblot ofIFN-gfrommonkeybrainsamples.Tissueof the
SNpcfromsevendifferentmonkeys(1–7)isshown.TheParkinsonianmotorscoreofthemonkeysisindicatedbetweenbrackets.GAPDHwasusedashouse-keepingprotein.
The analysis of the optical density of all the studied monkeys, normalized with GAPDH, is represented in Table 2. (d) Multiple ﬂuorescence labeling revealed that IFN-g (red)
co-localizewith microglial markerIba-1 (green) (1). However, astrocytemarker GFAP (green) did not co-localizewith IFN-g-expressingcells (red) (2). DAPI staining was used
to mark the cell nuclei (Blue). Scale bar: 50mm. (e) Higher magniﬁcation of two representative IFN-g
þ microglial cells. Some of the microglial cells with resting phenotype (1)
presented IFN-g staining mainly conﬁned to the cytoplasm (red) surrounding the cell nucleus (Blue). Other microglial cells with activated phenotype (2) presented IFN-g
stainingthroughthewholecytoplasm.(f)PercentageofIFN-g-expressingmicroglia(blackpieportion(Iba-1
þ/IFN-g
þ cells))overtherestofthemicroglialpopulation(graypie
portion (Iba-1
þ/IFN-g
  cells)) in the three group of animals. *Po0.05 (one-way ANOVA and Tukey’s test)
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Cell Death and DiseasenumberofF4/80
þ cellswasobservedand,second,thesizeof
the microglial cells did not increase after MPTP treatment
(Figures 6b-eand Table 3).However, the number of branches
did increase in IFN-g KO mice, which suggests that this
phenotypical change in the microglia is not dependent on
this cytokine. On the other hand, in mice lacking TNF-a (TNF-
a( / )), the microglial cells were slightly activated, as seen
from a slight increase in numbers (F4/80
þ cells) and size and
also an increased number of branches and tips (Figures 6b-e
and Table 3), suggesting that TNF-a has a synergistic co-
adjuvant role in activating microglia.
IFN-c signaling with TNF-a contribution is necessary for
astroglial activation. Concomitantly, we observed that
wild-type mice (C57BL-6) show a speciﬁc activation of
astroglial cells in the SNpc, characterized by an increased
number of GFAP
þ cells (Figures 6b and c), a larger cell body
size (Figures 6c and d) and also by an increased number
of secondary branches and terminal tips (Figures 6c–e).
Importantly, the absence of IFN-g or TNF-a prevented any
increase in the number of astrocytes (GFAP
þ cells) in the
SNpc after MPTP treatment (Figure 6b). On the other hand,
reactive GFAP cells showed the characteristic size change
after MPTP treatment and a slight increase in the number of
secondary branches and tips in IFN-g KO animals, which
suggests that IFN-g is not necessary for these morphological
changes (Figures 6b–e). However, the area occupied by
GFAP
þ cells and the number of branches and terminal tips
did not change in mice lacking TNF-a (TNF-a( / )),
demonstrating that TNF-a is crucial for the characteristic
phenotypical changes of astrocytes after MPTP intoxication
(Figures 6d and e).
Discussion
In the present work, we show that the persistent release of
IFN-g and TNF-a, among other pro-inﬂammatory cytokines, is
a crucial factor for perpetuating glial activation in Parkinsonism
(Figures 1, 2, 5, 6 and Supplementary Figure 1) and
importantly, may contribute to neuronal degeneration. This
is important, as it narrows down to two the putative speciﬁc
targets to be hit to diminish the glial-mediated inﬂammatory
Table 2 Pearson’s correlation between the amount of cytokines (IFN-g or TNF-a) measured in the SNpc of monkeys by western blot and (1) the motor impairment,
(2)dopaminergiccelldeathand(3)activationofmicrogliaorastroglia,measuredbythenumberofactivatedcells(HLA-DRformicrogliaandGFAPforastroglia)orthe
change of glial phenotype
Microglial activation Astroglial activation
Motor impairment Dopaminergic cell death Number HLA-DR Phenotype Number of GFAP Phenotype
IFN-g 0.91**  0.99*** 0.81
+ 0.95*** 0.51ns 0.89*
TNF-a 0.68
+  0.63
+ 0.55ns 0.47ns 0.38ns 0.57ns
Values of signiﬁcance for Pearson’s correlation:
nsP¼0.1 (non-signiﬁcant),
+Pr0.05, *Po0.02, **Po0.01, ***Po0.001
Figure 3 Microglial and astroglial cells express IFN-gR in the SNpc of MPTP-treated monkeys. (a and b) Sections of the SNpc of MPTP-treated monkeys were immuno-
stainedforIFN-gR(Green),combinedwitheitherastrocytemarkerGFAP(Redina)ormicroglialmarkerIba-1(Redinb)andcounterstainedwithDAPI(Blue).Scalebars:ina,
50mm; in b,4 0mm
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Cell Death and Diseaseresponse in Parkinsonism. By doing so, reducing speciﬁcally
the exacerbated glial reaction in the SNpc, DA neurons may
be beneﬁced and protected. Our results show that such glial
activation is speciﬁcally mediated by IFN-g signaling, aided by
TNF-a, and suggest that both cytokines are responsible for
enhancing the activation of the surrounding glial cells in a
reciprocal manner and that a degree of intercellular crosstalk
through both pro-inﬂammatory cytokines is needed to achieve
full activation of both cell types.
As we demonstrated with KO mice experiments, the
selective absence of IFN-g or TNF-a inhibits the activation of
microglial and astroglial cells in different ways. Importantly,
the absence of INF-g alters the activation of both glial cells,
especially the microglia, after MPTP treatment, which
demonstrates that IFN-g signaling is a crucial cytokine for
such activation in Parkinsonism (Figure 6). Furthermore, the
amount of IFN-g protein in the CNS correlates with glial
activation in chronic MPTP monkeys, but especially with the
Figure 4 Persistent phosphorylation of STAT1 (pSTAT1) in the SNpc of chronic Parkinsonian monkeys. (a–e) Panel (a) shows confocal images of pSTAT1 in a
representative image of the SNpc of a control monkey, asymptomatic and Parkinsonian monkey. DAPI staining is combined to observe the cell nuclei (Blue). High levels of
pSTAT1staining(Red)canbeseeninParkinsonianmonkeys.Scalebar:100mm.(b)QuantiﬁcationofpSTAT1
þ cellsintheSNpcofcontrol,asymptomaticandParkinsonian
monkeys. A strongly signiﬁcant increase can be observed in Parkinsonian monkeys. **Po0.01 (one-way ANOVA and Tukey’s test). (c) The pSTAT1 immunostaining in the
SNpc identiﬁed astroglia-like cells (1) and microglia-like cells (2). Scale bar: 30mm. (d) The pSTAT1 immunostaining (Red) was combined with GFAP or Iba-1 antibodies
(Green)andbothastrocytes(GFAP)andmicroglia(Iba-1)wereseentoco-localizewithpSTAT1.NucleiwerestainedwithDAPI(Blue).Scalebar:20mm. (e)Illustrationof the
IFN-g signaling, characterized by the phosphorylation of STAT1, through the activation of IFN-g receptor (IFN-gR) in a microglial cell and an astrocyte
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Cell Death and Diseasephenotypical changes in microglia (Table 2). This activation
may be induced and perpetuated by initiation of the STAT1
pathway through stimulation of the IFN-gR present in
microglialandastroglialcells
15,16(Figure3).Thisisconsistent
with the evidence of STAT1 phosphorylation observed in
astrocytes and microglial cells in the SNpc of Parkinsonian
monkeys (Figure 4) and is concordant with previous results
reported in other inﬂammatory scenarios in the CNS .
On the other hand, besides the action of IFN-g, the
contribution of TNF-a also seems to be important for glial
activation in Parkinsonism, especially for astrocytes. This is
consistent with the fact that astrocytes are able to release
TNF-a and, at the same time,can also be stimulated byTNF-a
invitro.
17,18 Thisactivation maybeparticularlyrelatedwiththe
morphology of astrocytes, because the lack of TNF-a results
in the absence of phenotypical changes after MPTP insult in
Figure 5 Persistent increase of TNF-a in the CNS of chronic Parkinsonian monkeys. (a–f) Increase of TNF-a
þ cells in the SNpc of Parkinsonian monkeys. (a) Confocal
images of immunoﬂuorescence against TNF-a revealed higher levels in Parkinsonian animals. Scale bar: 100mm. (b) The density of cells was estimated by stereological
criteria and a signiﬁcant increase of TNF-a
þ cells were observed in Parkinsonian animals. (c) Western blot of TNF-a from monkey brain samples. Tissue of the SNpc from
seven different monkeys (1–7) is shown. The Parkinsonian motor score of the monkeys is indicated between brackets. GAPDH was used as house-keeping protein. TNF-a
was speciﬁcally detected in the expected band in the SNpc of MPTP-treated monkeys. The quantiﬁcation of the optical density of all the analyzed monkeys, normalized with
GAPDH,is represented in Table2. (d)Multiple ﬂuorescencelabelingrevealedthat TNF-a (red) didnot co-localizewith microglialmarker Iba-1(green)(1). However,astrocyte
markerGFAP(green)co-localizedwith TNF-a-expressingcells(red)(2). DAPIstainingwasusedto markthecellnuclei(Blue).Scalebar:25mm.(e)Highermagniﬁcationof a
representative TNF-a
þ astrocyte. (f) Percentage of TNF-a-expressing astrocytes (black pie portion (GFAP
þ/TNF-a
þ cells)) over the rest of the astroglial population (gray
pie portion (GFAP
þ/TNF-a
  cells)) in the three group of animals. *Po0.05 (one-way ANOVA and Tukey’s test)
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Cell Death and DiseaseFigure 6 IFN-g and TNF-a have a cell speciﬁc function in microglial and astroglial activation. (a–f) Activation of the microglia depends on IFN-g and activation of the
astrocytes depends on TNF-a.( a) Quantiﬁcation of TH
þ neurons in the SNpc revealed no signiﬁcant reduction of dopaminergic neurons in any of the experimental groups
24h after MPTP. (b) Quantiﬁcation of the number of F4/80
þ microglial cells and GFAP
þ astroglial cells. In the absence of IFN-g, no increase in the number of F4/80
þ or
GFAP
þ cells was observed after MPTP treatment. In the absence of TNF-a, a slight increase of F4/80
þ cells was observed, but no changes were noted in the number of
GFAP
þ cells. *Po0.05 (one-way ANOVA and Tukey’s test). (c) Confocal pictures of microglial cells (Iba-1) and astroglial cells (GFAP) in the SNpc of wild type mice
(C57 BL6), IFN-g KO mice (IFNg( / )) and TNF-a KO mice (TNF-a( / )). Scale bar: 30mm. (d) Quantiﬁcation of the area occupied by Iba-1 demonstrates that the size of
microglial cells (Iba-1) increases signiﬁcantly after MPTP treatment. However, in the absence of IFN-g, the microglial cells do not change their size. In TNF-a( / ) mice,
microglial cells also increase their size, but to a lesser extent. Quantiﬁcationof the area occupiedby GFAP demonstrated that the size of astroglial cells increases after MPTP
treatment. In the absence of IFN-g, astroglial cells also increase their size after MPTP; however, in the absence of TNF-a, astroglial cells remain unchanged after MPTP.
*Po0.01 with respect to control saline values,
wPo0.01 with respect to wild type C57 MPTP (one-way ANOVA and Tukey’s test). (e) Quantiﬁcation of primary branches
(1ary), secondary branches (2ary) and terminal tips (T) in microglial (Iba-1) and astroglial cells (GFAP). Both microglial and astroglial cells change their phenotype 24h after
MPTP treatment in wild-type animals (C57BL6). In animals without IFN-g (IFNg( / )), microglial cells show no changes in primary branches, but increased numbers of
secondary branches and terminal tips. In TNF-a KO animals (TNFa( / )), microglial cells show increased numbers of primary, secondary branches and T. However,
astroglial cells remain unchanged in TNF-a( / ) mice 24h after MPTP. *Po0.01,
.Po0.05 (one-way ANOVA and Dunnett’s test)
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probably enhancing glial activation by the stimulation of the
TNF-aR present in astroglial cells,
19 which suggests that
astrocyte activation may be also relevant for the activation of
surrounding astrocytes.
TNF-a and IFN-g showed high levels over several years
followingMPTPtreatmentinourmonkeys(Figures2and5)as
occurs in PD patients,
8–10,20 which may have contributed to
the long-term glial activation observed and consequently to
dopaminergic loss. Importantly, the amounts of both, IFN-g
and TNF-a in the SNpc correlate with the degree of
neurodegeneration and motor impairment (Table 2). In line
with this, previous reports showed that centrally and systemi-
cally circulating cytokines may exacerbate neurodegenera-
tion in Parkinsonian rats, suggesting that the expression of
cytokines in the CNS and also in the blood stream may be
crucial for full glial activation and dopaminergic degenera-
tion.
21
Unlike in primates, mice do not show such persistently
increased cytokine levels in the blood 24h after MPTP insult
(Supplementary Figure 5), which may be consistent with
transient glial activation.
22–24 In fact, previous reports have
shown that MPTP-treated mice merely show a transitory
increase in pro-inﬂammatory cytokines from 24h to 72h after
MPTP insult, which may explain why only some pools of our
mice showed increased levels of IFN-g and TNF-a after MPTP
(Supplementary Figure 5).
22–25 Furthermore, the perceptible,
but transient increase in cytokine levels in mice after MPTP is
also dependent on the MPTP treatment regime, and may only
be observed in protocols involving chronic administration.
23
Our results also suggest that glial cells may be one of the
main cells responsible for IFN-g and TNF-a release in the
CNS. We ﬁrst demonstrated that IFN-g is highly increased in
the SNpc, as demonstrated by immunohistochemistry and
western blot analysis. Surprisingly, microglial cells and not
astrocytes showed a high degree of IFN-g expression in the
SNpc of monkeys (Figure 2). The possibility of a role for cells
of myeloid origin, such as macrophages/microglia, as an
additional source of IFN-g is controversial and has received
little attention (for review on this matter see ref. 26). In depth
studies have shown strong evidence that macrophages/
microglia are able to synthesize IFN-g mRNA and produce
IFN-g protein in both resting and activated states.
27,28 After
activation, macrophages/microglia show higher levels of
IFN-g and its release may have a crucial role in the activation
of neighboring cells and conduct the local inﬂammatory
response.
26–28 Importantly, the detection and imaging of
IFN-g protein in resting or activated macrophages has been
elusive, and confocal immunoﬂuorescence is the preferable
technique for its cell-associated detection (see review ref. 26,
pg. 288, 2nd paragraph).
Interestingly, the expression of IFN-g can be observed in
both microglial cells with or without an activated phenotype
(Figure 2e). IFN-g
þ microglial cells with resting phenotype
show peri-nuclear staining of IFN-g (Figure 2e1). However,
IFN-g
þ microglial cells with activated phenotype show a high
content of IFN-g in the cytoplasm, suggesting that highly
activated microglia may be able to produce, release or
accumulate large amounts of IFN-g (Figure 2e2). Control
animals showed a small percentage of IFN-g-expressing
microglia, which signiﬁcantly increased in MPTP-treated
monkeys (Figure 2f).
In contrast, TNF-a is highly expressed in astrocytes, but not
in microglia in the SNpc of monkeys (Figure 5). TNF-a
immuno-reactivity is observed very close to GFAP expression
in reactive astrocytes (Figure 5e), which suggests that TNF-a
synthesis and/or release may be intimately linked with the
astrocyte cytoskeleton. TNF-a-expressing astrocytes could
also be seen in control animals, but their expression and
percentage increased in Parkinsonian monkeys (Figure 5f).
Recent experiments performed in vitro have concluded that
microglial cells are the initial responders to inﬂammation and
suggest that astrocytes may amplify the production of
neurotoxic factors after microglial activation.
29 These ﬁndings
are consistent with the idea that the release of IFN-g by
microglial cells is important for the initiation and maintenance
of microglial and astroglial activation in combination with
TNF-a. Importantly, increasing evidence points to the TNF-a
released by astrocytes as having a deleterious impact on
dopaminergic neurons, as previously described in vitro,
30
stimulating the TNF-aR present in the neuron membrane.
31
Our results in chronic Parkinsonian monkeys, however,
revealed that IFN-g correlates more strongly with dopaminer-
gic loss than TNF-a, suggesting a prominent role for IFN-g in
cell death.
We conclude that IFN-g and TNF-a are clearly crucial
players in microglial and astroglial activation in Parkinsonism
and may be critical factors in the local perpetuation of glial
activation in the SNpc, contributing to dopaminergic neuronal
degeneration and motor impairment. This strongly suggests
that targeting both cytokines may be a suitable therapy for
reducing this glial-mediated inﬂammation in PD.
From a clinical point of view, an abundance of data show
that anti-inﬂammatory treatment may be beneﬁcial for
Table 3 Summary of the results obtained from the analysis of microglia and astroglial activation in the SNpc after MPTP treatment of wild type (C57BL6), IFNg( / )
and TNFa( / ) mice
Microglia Increase of F4/80
+ cells Increase in # of branches and tips Increase of cell body size
C57BL6 +++ +++ +++
IFNg( / )   ++  
TNFa( / ) + +++ ++
Astroglia Increase of GFAP
+ cells Increase in # of branches and tips Increase of cell body size
C57BL6 +++ +++ +++
IFNg( / )   +++ +++
TNFa( / )     
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32 Neuropathological examinations
suggest that persistent glial activation in humans may be
responsible of exacerbating the inﬂammatory environment
and contribute to neuronal degeneration.
1,3 Some anti-
inﬂammatory drugs have been reported as having an impact
on the development of the disease
32 and, interestingly, a
polymorphism, precisely in the HLA-DR gene, has recently
been described as a putative gene that may affect the
susceptibility to PD.
33 It is therefore important to tackle the
exacerbated glial response, but only targeting the precise
mechanisms. In particular, the development of speciﬁc
antibodies that avert cytokine activity represents a promising
therapy for many CNS disorders.
34 We propose that the
manipulation of both these pro-inﬂammatory cytokines, IFN-g
and TNF-a, which seem to contribute to dopaminergic
neuronal degeneration, could well be relevant for PD therapy
in the near future.
Materials and Methods
Parkinsonian monkeys. The present study uses blood samples and brain
tissuefromacolonyofchronicParkinsonianmacaques(Macacafascicularis),which
have been studied for several years in our Primate Unit. All studies were carried out
in accordance with the Guidelines of the European Convention for the protection of
vertebrate animals used for experimental and other scientiﬁc purposes of the
Councilof Europeof 2006, the HelsinkiDeclaration,the InternationalPrimatological
Society Guidelines and the Guide for the Care and Use of Laboratory Animals (NIH
Guide, revised 1996). Samples obtained from 20 young adult animals of both sexes
were analyzed. A total of 14 animals at 4 years of age were treated with low weekly
intravenous doses of MPTP (0.3mg/kg) according to previous protocols.
35 As each
individualhasaverydifferentsusceptibilitytoMPTP,thenumberofinjectionsvaried
depending on the systemic response to the toxin and the motor score reached. The
treatment with MPTP was stopped when: (1) a stable Parkinsonism was achieved,
or (2) when the individual displayed a systemic response that was considered
potentially lethal or (3) when new injections do not affect the motor score (Table 1).
None of them received L-DOPA or dopaminergic agonizts. The animals were
observed by different researchers after each dose and as the Parkinsonian
syndrome progressed. Motor symptoms were assessed using a previously
described scale ranging from 0 to 25.
35 The degree of disability normally
increased with every new injection and remained stable for years. Animals showing
evident Parkinsonian symptoms after MPTP injection as well as clear impairment of
their motor score were classiﬁed as Parkinsonian. Animals with no apparent
Parkinsonian symptoms after MPTP administration were considered asymptomatic.
Non-MPTP-treated animals were grouped as controls (Figure 1 and Table 1). This
classiﬁcation provided a population of subjects similar to the scenario that occurs in
humans, where symptomatic patients show more than 80% dopaminergic loss,
while some individuals remain asymptomatic despite a starting neurodegenerative
process.Wewerenotabletogrouptheanimalsintosmallersubgroups(e.g.degree
of Parkinsonism or time of survival after MPTP administration) because the sample
would have been too small to ascertain statistically signiﬁcant differences. Animals
were killed from 1 to 5 years after the last MPTP administration (Table 1).
MPTP mice. Ten-week-old male knockout mice B6.129S7-Ifng
tm1Ts/J, TNF-a
knockoutmiceB6.129S-Tnf.
tm1Gkl/JandcorrespondingparentalWTinbredC57BL/
6J mice were purchased from JaxMice (The Jackson Laboratory, Bar Harbor, ME,
USA). The mice were housed in a special room with adequate temperature (211C)
and 12h day–night cycles. Mice were injected (by intraperitoneal injection) either
with a single dose of MPTP (20mg/kg) or the same volume of saline and killed 24h
after the single injection (n¼6 per group). All studies were carried out in
accordance with the Guidelines of the European Convention for the protection of
vertebrate animals used for experimental and other scientiﬁc purposes of the
CouncilofEuropeof2006, theHelsinkiDeclarationandtheIACUCoftheUniversity
of Murcia.
ELISA determination of IFN-c and TNF-a
Monkey serum extraction. IFN-g and TNF-a concentrations in monkey blood
serum were determined by ELISA detection kit (human IFN-g and human TNF-a,
e-biosciences,SanDiego,CA,USA).Towithdrawthebloodsamples,2daysbefore
killing, the monkeys were restrained in their own cage by a movable back wall and
the extraction was made through the saphenous vein using a sterile 5ml syringe
andintravenousneedleatbetween09:00and10:00hours.Nosedativewasusedto
take the samples. The serum samples were obtained by centrifugation of the
individual blood samples at 3600r.p.m. for 10min at room temperature. The
resultant supernatant was aliquoted and stored at  801C until analysis.
Mouse serum extraction. IFN-g and TNF-a concentrations in mouse blood
serum were determined by ELISA detection kit (mouse IFN-g and mouse TNF-a,
e-biosciences).Towithdrawthebloodsamples,micewereanesthetized24hafterMPTP
injection with ketamine/xylazine for perfusion ﬁxation. Before the perfusion, blood was
obtained by intra-cardial extraction. The serum samples were obtained by centrifugation
of the individual blood samples at 3600r.p.m. for 10min at room temperature. The
resultant supernatant was doubly concentrated using a centrifugal ﬁlter device (Microcon
YM-10, Millipore, Bedford, MA, USA) and pools of three mice were made to reach
perceptive values. Serum samples were stored at  801C until analysis.
ELISAprotocol. Samplesfrombothmiceandmonkeyswereprocessedwiththe
following ELISA protocol. The 96-well microplates were coated with the capture
antibodyovernightat 41C. Theplates werethen washedthree timeswith a washing
buffer (PBSþ0.05% Tween 20), and 100ml of a blocking buffer were added to
each well before incubating for 1h at room temperature. Subsequently, the plates
were incubated with standards and appropriate dilution of the samples for 1h at
room temperature (hemolyzed serum samples were discarded). After ﬁve washes,
thesecondaryantibodywasaddedtothewells,andtheplateswereagainincubated
for 1h at room temperature. The plates were then washed seven more times and
incubated with revealing solution for 15min. The reaction was stopped by adding
50mlo f2 NH 2SO4. The absorbance of each well was measured at 450nm, using a
microplate reader.
Tissue and speciﬁc staining
Monkeys. The monkeys were killed with a lethal pentobarbital injection after
ketamine anesthesia 1, 2 or 5 years after the last MPTP dose (Table 1). The brains
were then removed and one brain hemisphere was rapidly frozen with dry ice and
stored at  801C for western blot analysis. The other half was ﬁxedfor 3 daysin 4%
paraformaldehyde dissolved in 0.1M phosphate buffer. The ﬁxed mesencephalon
was sectioned into 40mm thick serial sections (Microm, HM400). Series of sections
regularly spaced at intervals of 1440mm were stained for tyrosine hydroxylase (TH)
(sheep polyclonal antibody 1:500; Chemicon, Temecula, CA, USA) to quantify the
loss of dopaminergic neurons in the MPTP-intoxicated monkeys; for GFAP (rabbit
polyclonal antibody 1:500; Chemicon) to analyze the putative astrogliosis in the
SNpc of the Parkinsonian monkeys; for Iba-1 (rabbit polyclonal antibody 1:500;
Wako, Chuo-Ku, Osaka, Japan) to determine the population and phenotype of
microglial cells; for human leukocyte antigen-DR (HLA-DR) a-chain CR3/43 clone;
(mouse monoclonal antibody 1:50; Dako, Carpinteria, CA, USA) to observe the
microglial activation. Antibodies were also used to detect the expression of
cytokines in the SNpc: anti-human IFN-g (mouse monoclonal, 1:100, R&D,
Minneapolis, MN, USA) and anti-human TNF-a (mouse monoclonal, 1:100, R&D).
We also used speciﬁc antibodies to detect IFN-g receptor (IFN-gR) (mouse
monoclonal antibody 1:100; Fitzgerald Industries International, Acton, MA, USA)
and phosphorylated STAT1 (pSTAT1) (mouse monoclonal antibody 1:100;
Invitrogen, Carlsbad, CA, USA). Sections from all the animals were stained
simultaneously and under the same experimental conditions.
Mice. OnedayafterMPTPinjection,micewereanesthetizedintraperitoneallywith
an overdose of ketamine (50mg/kg) and xylazine (50mg/kg) and perfused-ﬁxed
with oxygenated Tyrode’s solution followed by 4% paraformaldehyde in PBS. Brain
tissue was removed and post-ﬁxed for 48h before sectioning and further analysis.
All animal experiments were performed after previous approval and conformed to
the policies and procedures of the University of Murcia.
The mesencephalon and the striatum were sectioned into 40mm thick serial
sections (Vibratome, Leica Microsystem, Wetzlar, Germany). Series of regularly
spaced sections were stained for tyrosine hydroxylase (TH) (sheep polyclonal
antibody 1:500; Chemicon); for GFAP to observe astroglial activation (rabbit
monoclonal antibody 1:500; Chemicon); for F4/80 (rat antibody 1:50; Serotec,
Kidlington, UK) to detect microglial activation and for Iba-1 (rabbit polyclonal
antibody 1:500; Wako) to study the microglial phenotype.
Immunohistochemistry and immunoﬂuorescence
DAB detection. For immunohistochemistry, sections of the SNpc (40mm) were
used to detect speciﬁc cells. Endogenous peroxidase activity was inhibited with
0.3% H202 and non-speciﬁc Fc binding sites were blocked with 10% horse serum.
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antibody(see above) diluted in PBS containing 1% horse serum, 0.5% Triton X-100
and 0.1% sodium azide. Sections were incubated for 4h in secondary antibody
diluted in antibody solution. Antibody binding was detected with the avidin-biotin
peroxidaseABCkit(Vectastain,VectorLabs,Burlingame,CA,USA).Sectionswere
mounted on gelatin-coated slides and dehydrated in a graded ethanol series and
xylene before being coverslipped.
Immunoﬂuorescence. For immunoﬂuorescence, 40mm sections were treated
with 0.5% citrate buffer (651C, with constant shaking) for 30min to maximize
antibodypenetrationinto thetissue.Non-speciﬁcFc bindingsites wereblocked with
10% horse serum, and sections were incubated for 48h (room temperature,
constant shaking) with primary antibody diluted in PBS containing 1% horse serum,
0.5% Triton X-100 and 0.1% sodium azide. Sections were incubated for 4h in
labeled secondary antibody and, after PBS washes, sections were incubated with
DAPI solution (Molecular Probes, Carlsbad, CA, USA) (1:1000) in 1  PBS for
30min. Sections were then washed, mounted and examined to quantify the
ﬂuorescently labeled cells by conventional microscopy (Zeiss Axioplan 2, Standort
Go ¨tingen, Germany), or using confocal microscopy (Leica DMIRE2, Wetzlar,
Germany).Appropriatesecondaryantibodieswereused:Alexa488-conjugatedand
Alexa 594-conjugated (1:1000) (Molecular Probes).
Histological quantiﬁcation. SNpc was deﬁned according to the Monkey and
Mouse Brain Atlas.
36,37 DAB or ﬂuorescently labeled cells were quantiﬁed in serial
coronal sections from each animal. The number of cells was estimated by optical
fractionator probe using a computer assisted image analysis system with a Zeiss
Axioplan 2 microscope connected to a digital camera. The region of interest was
traced using the  1.25 objective. The number of cells was measured in
200 200mm dissectorscoveringthesurface of theanalyzedregion.Labeledcells
were counted using the  40 objective and counting frames over the delineated
area of the SNpc in each section (optical fractionator). Two representative sections
of the SNpc were used for each stain in monkey brains. These representative
sections were chosen according to the criteria previously deﬁned by Olzewsky and
Baxter.
38 The sections contained the ventrolateral area of the SNpc (in primates
corresponding to the aþb area at the level of the III cranial nerve output), which is
known to show the highest degree of dopaminergic loss and glial activation in
humans
39 and non-human primates.
35 Four sections of the SNpc were used for
eachstaininmousebrain.Thedataareexpressedasthedensityofcellspermm
3in
each anatomical region analyzed. Results are expressed as the mean±S.E.M.
Confocal analysis. Brain sections were examined using a Leica DMIRE2
confocalmicroscopewiththe  63oilobjectiveandLeicaConfocalSoftware(Leica
Microsystems, Wetzlar, Germany). A series range for each section was set by
determining an upper and lower threshold using the Z/Y position for spatial image
series (for further details see previous publications
40). Images can be illustrated as
they appear throughout the stack of sections as a simple 0.5mm layer or as a
transparency of all layers merged together.
Quantiﬁcation of activated glial phenotype. The activated glial state was
characterized by the expression of speciﬁc reactive proteins as described below
(HLA-DR or F4/80 for human or mice microglia, respectively, and GFAP for
astroglia), but also according to the change of phenotype (See Supplementary
Figure 6). To study the glial phenotype, serial sections along the SNpc from
monkeysormicewerestainedbyimmunoﬂuorescenceto observemicroglial(Iba-1)
or astroglial (GFAP) cells. Sections were scanned with confocal microscope as
described above and primary and secondary branches were quantiﬁed along the
z axes in more than 10 cells per animal (more than 50 cells per group). Primary
branches were considered as the ﬁrst ramiﬁcation emerging from the cell body and
secondary branches as the ramiﬁcation emerging from the primary branches. The
microglial or astroglial area was quantiﬁed using confocal images of Iba-1 or GFAP.
Scanned confocal planes of 0.5mm containing Iba-1 or GFAP-labeled cells were
processedwithImage-Jimagesoftware(NationalInstituteofHealth,Bethesda,MD,
USA) to obtain a black and white image. The area occupied by 50 microglial cells of
the SNpc of each animal was measured in these processed images. The area
occupied by astroglial cells was not measured in monkeys because their processes
werecompletelyintermingledandthesoftwarewas unabletodistinguishanddeﬁne
each individual cell unit. All quantiﬁcations were made blindly by two different
researchers (CMR and MEM).
Western immunoblot
Primaryantibodies. TotestthespeciﬁcityoftheantibodiesusedtodetectIFN-g
and TNF-a in the SNpc of monkeys, a western immunoblot was performed with anti
TNF-a, diluted 1:200 (R&D systems) and Mouse anti IFN-g, diluted 1:200 (R&D
systems). GAPDH antibody was used to determine the housekeeping of each
sample (mouse anti GAPDH, 1:500, Chemicon).
Preparation of tissue extracts. The SNpc from the frozen half of the tissue of
the monkeys kept at  801C (see details above) was dissected according to the
appropriate coordinatesgivenby the monkeybrainatlas,
37 usinga punchingdevice
designed in our lab of 0.5cm internal diameter. Tissues were immediately
homogenizedwitha disposablepelletpestle(Sigma-Aldrich,St.Louis,MO,USA)in
RIPA buffer, containing 50mM tris/HCl pH 7.6, 150mM NaCl, 1mM EDTA, 1%
SDS, 1% Triton X-100, 1x cocktail inhibitor (Sigma-Aldrich), 1mM PMSF, 0.2mM
Na3VO4 and 1mM NaF. After centrifugation (15000 g for 15min at 41C), a
speciﬁc volume of supernatant was analyzed to determine the total concentration of
the protein in thesample using theMicroBCA kit (Pierce, Rockford,IL, USA). Other
aliquots of the samples were mixed with 4  reducing loading buffer (200mM Tris/
HClpH6.8,4%SDS,30%glycerol,4%b-mercaptoethanol,4%bluebromophenol),
boiled for 3min and stored at  201C until use.
Electrophoresis and immunoblotting. For each sample, 80mg of proteins
were separated on 15% SDS-polyacrylamide gels. Molecular mass standard
(ColorBurst, Sigma-Aldrich) containing the precisely sized recombinant proteins of
210, 90, 65, 40, 30, 20, 13, 8kda, positive controls of human recombinant TNF-a
(80ng)orhumanrecombinantIFN-g(80ng)(R&Dsystems),andthesamplesofthe
SNpcwereruninthesamegelandtransferredontoanitrocellulosemembrane.The
samples were run at constant voltage (200mV) room temperature (RT) for 1h.
After electrophoresis, protein samples were transferred onto a nitrocellulose
membrane using a transfer buffer (25mM Tris/HCl, 192mM glycine, 0.1% SDS,
20% methanol). Pounceau S staining (Bio-Rad, Hercules, CA, USA) was used to
verify equal protein loading in all the lanes.
Non-speciﬁc biding sites were blocked by incubation in 5% dry milk diluted in
TTBS1X(20mMtris/HClpH7.5,500mMNaCl,0.05%tween-20)for2hatRT.The
membranes were incubated overnight at 41C in the primary antibody diluted in 3%
BSA, 0.05% NaN3, in TTBS 1x. After rinsing twice with TTBS 1  and thrice with
2.5% dry milk in TTBS 1X, the membranes were incubated for 1h at RT in ECL
sheep anti mouse IgG, horseradish peroxidase conjugated secondary antibody
(GE healthcare, Little Chalfont, UK) diluted 1:5000 in 2.5% dry milk in TTBS 1 .
Antibody binding sites were revealed using ECL plus the western blotting
detection system (GE healthcare). The intensity of the bands was evaluated by
densitometric analysis using ImageJ 1.41 software. The optical density of each
protein band was normalized against the optical density of the GAPDH band used
as internal standard on the same lane. For each independent experiment, the
differences between the experimental groups were expressed as treated/control.
The graphs represent the average of the ratios calculated from ﬁve independent
experiments±S.E.M.
Statistical analysis. Data are expressed as mean±S.E.M. Statistical
analysis was performed using a t-test or one-way ANOVA test following a
posthocanalysis(followedbyDunnetorTukeymultiplecomparisonstests).Thenull
hypothesis was rejected for an a risk equal to 5%.
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